Table 3.

Reproducibility of drug susceptibility assay starting with plasmaa

SamplebFold change in susceptibility (IC50 for sample virus/IC50 for reference virus)
NRTINNRTIPRI
ZDVddId4TddC3TCNVPDLVSQVIDVRTVNFVAMP
178A39.81.401.571.77c 0.380.273.126.4212.053.973.24
178B51.11.712.021.760.520.423.096.0925.407.043.67
268A37.12.502.122.141.1323.991.020.334.75.23
268B30.02.862.251.881.4528.4121.421.936.53.69
372A2.791.221.462.20194.50.764.415.893.362.25
372B2.671.861.131.17236.1145.62.089.665.845.062.15
644A1.041.240.84NDd 1.56581.22.781.003.564.405.050.90
644B2.170.980.641.090.82622.31.780.472.174.572.420.68
648A1.510.561.150.640.831.001.590.370.930.9011.140.43
648B1.360.700.801.140.480.881.990.321.360.6915.480.31
649A3.330.990.720.710.920.370.621.171.712.092.012.30
649B2.810.830.710.820.930.380.591.622.032.003.422.87
675A5.091.751.081.964.701.450.920.861.812.290.36
675B4.032.311.152.157.332.730.920.532.222.100.51
682A21.41.512.830.660.170.2129.132.16203.2121.710.8
682B38.91.833.861.150.260.1037.442.31136.8167.38.87
686A22.10.872.020.373.500.150.1837.233.18203.897.213.9
686B15.50.740.920.722.010.200.1453.937.60135.673.719.4
  • a Duplicate aliquots of nine patient plasma samples were processed in parallel.

  • b Patient virus genotypes were as follows: sample 178, RT, M41L, D67N, K70R, M184V/I, L210W, and T215Y; PR, L10V, M46I/L, L63P, A71T/V, V82T, and I84V; sample 268, RT, M41L, D67N, K103K/N, M184V, L210W, T215Y, K219Q, and P236P/L; PR, L10I, K20R, M36I, I54V, L63P, A71V, V82T, I84V, and L90M; sample 372, RT, D67N, T69D, K70R, K103N, M184V, and K219Q; PR, M46I and A71V; sample 644, RT, K101E and G190S; PR, L10I, L63P, A71T/I, V82T, and L90L/M; sample 648, RT, K70K/R and T215T/Y; PR, K20R, D30N, M36I, L63H, and A71V; sample 649, RT, D67N, and K219Q; PR, L10I, and L63A; sample 675, RT, M41L, L74V, A98G, M184V, and T215Y; PR, L10I, M36I, L63S, and L90M; sample 682, RT, M41L, D67N, M184V, L210W, and T215Y; PR, L10I, K20K/R, M36I, M46L, I54V, L63P, A71V, V82A, and L90M; sample 686, RT, M41L, L210W, and T215F; PR, L10I, M46M/I, I54V, L63P, A71V, V82A, and L90M.

  • c —, no inhibition of luciferase activity was observed at the highest concentration of drug tested.

  • d ND, not determined.